Mepolizumab Monoclonal Antibody for Severe Asthma

English name：mepolizumab

CAS number：196078-29-2

molecular formula

Molecular weight: 0

EINECS No

Related category: drug substance; chemical reagent

The Mol file: Mol File

constitutional formula

Nature of mebolizumab

Storage conditions: Store at-20 C

Form: liquid

Color: colorless to pale yellow

Antibodies to severe eosinophilic asthma

On November 4,2015, the FDA approved GlaxoSmithKline's mAb injection, Memepimumab (Mepolizumab), marketed as Nucala. Meipolizumab is an experimental fully humanized monoclonal antibody that specifically targets interleukin 5 (IL-5) for the treatment of severe eosinophilic asthma. IL-5 is a cytokine that regulates the growth, activation, and survival of eosinophils (white Chemicalbook cells) and can provide important signals for the migration of eosinophils from the bone marrow to the lungs and other organs. Meibolumab binds to human IL-5, blocks the binding of IL-5 to the eosinophils surface receptors, in this way inhibiting the binding effect of IL-5 on the receptor, can reduce eosinophils in blood, tissues, and sputum, which in turn can reduce the inflammation mediated by eosinophils.

Mechanism of action

The active ingredient of mepobolumab Nucala is mepolizumab, a fully humanized monoclonal antibody that specifically targets interleukin 5 (IL-5). IL-5 is a cytokine that regulates the growth, activation, and survival of eosinophils (leukocytes) and can provide important signals for the migration of eosinophils from the bone marrow to the Chemicalbook of the lung and other organs. Meipolizumab Nucala binds to human IL-5 and blocks the binding of IL-5 to eosinophil surface receptors. Inhibiting the receptor-binding effect of IL-5 in this way is able to reduce the eosinophils levels in the blood, tissue, and sputum, which in turn is able to reduce the inflammation mediated by eosinophils.

Target spot

Interleukin-5

Use

Mempilumab (Mepolizumab), trade name Nucala, was FDA approved in November 2015 to treat severe and eosinophil phenotypic asthma in patients aged 12 years and older, becoming the first IL-5 antibody to receive FDA approved Chemicalbook, and subsequently expanding the applicable population to children aged 6-11 years in September 2019. In December 2017, the FDA approved the disease for the treatment of adult eosinophilic Wegener's granuloma (EGPA), becoming the first biological product to treat the disease.

security information

MSDS information

Hot Tags: mepolizumab monoclonal antibody for severe asthma, China mepolizumab monoclonal antibody for severe asthma suppliers, biologics biosimilars, Ipilimumab inhibitors, Infliximab Is A Chimeric Monoclonal IgG1 Antibody, 170277-31-3, biosimilar meaning, approved biosimilars